文献速递妇科产科

早期宫颈癌术前近距离放疗的系统综述与Meta分析

Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2022-11-29

该系统综述与Meta分析检索MEDLINE、Embase、Cochrane Central Register of Controlled Trials和Scopus数据库至2022年4月,纳入13项研究(3项随机对照试验和10项非随机研究),评估早期宫颈癌术前近距离放疗(PBT)的病理缓解率和肿瘤学结局。非随机研究中PBT组5年生存率显著高于直接手术组(OR 1.78,95%CI 1.11-2.84,I²=0%),随机对照试验中PBT组复发率显著低于直接手术组(OR 0.34,95%CI 0.13-0.91),但非随机研究中无显著差异(OR 0.72,95%CI 0.26-1.95,I²=51%)。PBT与更高的完全病理缓解率相关(随机对照试验OR 2.55,95%CI 1.11-5.85,I²=0%;非随机研究OR 9.64,95%CI 1.88-49.48,I²=76%),随机对照试验中PBT组切缘阳性率显著更低(OR 0.28,95%CI 0.09-0.89,I²=42%)。结论认为PBT可能改善病理和肿瘤学结局,但在临床实践实施前需通过高质量随机对照试验评估。

要点

  • 非随机研究中PBT组5年生存率显著高于直接手术组(OR 1.78,95%CI 1.11-2.84,I²=0%)。
  • 随机对照试验中PBT组复发率显著低于直接手术组(OR 0.34,95%CI 0.13-0.91),非随机研究中无显著差异(OR 0.72,95%CI 0.26-1.95,I²=51%)。
  • PBT组完全病理缓解率在随机对照试验(OR 2.55,95%CI 1.11-5.85,I²=0%)和非随机研究(OR 9.64,95%CI 1.88-49.48,I²=76%)中均显著高于直接手术组。

核心结论

  • 早期宫颈癌患者术前近距离放疗可能改善病理和肿瘤学结局,但在临床实践实施前应通过高质量随机对照试验评估。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、Cochrane Central Register of Controlled Trials和Scopus数据库自建库至2022年4月,仅纳入英文和法文文献,研究注册于PROSPERO(CRD42022319036)。
  • 纳入13项研究,包括3项随机对照试验(RCT)和10项非随机研究(NRS)。

主要发现

  • 非随机研究中,PBT组5年生存率显著高于直接手术组(OR 1.78,95%CI 1.11-2.84,I²=0%)。
  • 随机对照试验分析中,PBT组复发率显著低于直接手术组(OR 0.34,95%CI 0.13-0.91,I²不适用);非随机研究中两组复发率无显著差异(OR 0.72,95%CI 0.26-1.95,I²=51%)。
  • 随机对照试验中,PBT组切缘阳性率显著低于直接手术组(OR 0.28,95%CI 0.09-0.89,I²=42%)。
  • 完全病理缓解率在随机对照试验分析中PBT组显著高于直接手术组(OR 2.55,95%CI 1.11-5.85,I²=0%),在非随机研究中亦显著高于直接手术组(OR 9.64,95%CI 1.88-49.48,I²=76%)。

关键数值与推荐

  • 非随机研究中PBT组5年生存率显著高于直接手术组(OR 1.78,95%CI 1.11-2.84,I²=0%)。
  • 随机对照试验中PBT组复发率显著低于直接手术组(OR 0.34,95%CI 0.13-0.91,I²不适用);非随机研究中无显著差异(OR 0.72,95%CI 0.26-1.95,I²=51%)。
  • 随机对照试验中PBT组切缘阳性率显著低于直接手术组(OR 0.28,95%CI 0.09-0.89,I²=42%)。
  • 完全病理缓解率在随机对照试验中PBT组显著高于直接手术组(OR 2.55,95%CI 1.11-5.85,I²=0%),在非随机研究中亦显著高于直接手术组(OR 9.64,95%CI 1.88-49.48,I²=76%)。

临床怎么用

  • 作者认为术前近距离放疗可能改善早期宫颈癌患者的病理和肿瘤学结局,但在临床实践实施前应通过高质量随机对照试验评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the rate of pathological response rate, and the oncological outcomes of preoperative brachytherapy (PBT) in early-stage cervical cancer. METHODS: A systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and meta-analyses (PRISMA) statement. MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Scopus databases were searched from inception until April 2022. Only English and French articles were included. Studies containing data about pathology response or oncological outcomes among patients who received PBT as compared to those who underwent up-front surgery in early-stage cervical cancer were included. This study was registered in PROSPERO (CRD42022319036). RESULTS: Thirteen studies met the inclusion criteria, 3 randomized controlled trials (RCT), and 10 non-randomized studies (NRS). The 5-year survival was significantly higher in the PBT group compared with the up-front surgery group (OR 1.78, 95% CI 1.11-2.84, I2 = 0%) in the NRS. Recurrence rate was significantly lower in the PBT group compared with in up-front surgery group in the analysis of the RCT but not in NRS, (OR 0.34, 95% CI 0.13-0.91, I2 not applicable) and (OR 0.72, 95% CI 0.26-1.95, I2 = 51%) respectively. PBT was associated with a statistically significant lower rate of positive margins (OR 0.28, 95% CI 0.09-0.89; I2 = 42%) in the RCT and with a significantly higher rate of complete pathology response (CPR) in the RCT analysis (OR 2.55, 95% CI 1.11-5.85, I2 = 0%) and in the NRS (OR 9.64, 95% CI 1.88-49.48, I2 = 76%) compared with the up-front surgery group. CONCLUSION: Preoperative brachytherapy in patients with early-stage cervical cancer could improve pathologic and oncologic outcomes, but it should be assessed in high-quality randomized controlled trials before its implementation in clinical practice.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Vieira-Serna S, Viveros-Carreño D, Rodríguez J, et al. Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis. Gynecol Oncol. 2022. PMID: 36459858. doi:10.1016/j.ygyno.2022.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。